Summary
The neurotoxins produced byClostridium botulinum are the most potent acute toxins known and are the causative agents of the neuroparalytic disease botulism. The toxins act primarily at peripheral cholinergic synapses by blocking the evoked release of the neurotransmitter acetylcholine. There are seven distinct serotypes of toxin. All are polypeptides ofM r about 150 kDa that have similar structure and pharmacological action. In their most active forms the toxins exist as dichain molecules in which a heavy (H) chain is linked by disulphide bonding to a light (L) chain. The H chain is believed to be associated with the highly specific and avid binding of toxin to the motor nerve end plates and also with the process of internalisation of the toxin. The toxic activity appears to be associated with the L chain which blockades the calcium-mediated release of acetylcholine, probably by interfering at the molecular level with the mechanisms whereby neurotransmitter-containing vesicles merge with the plasmalemma. The type A toxin is now used therapeutically to treat a variety of conditions involving involuntary muscle spasm. The therapeutic toxin is a neurotoxin-haemagglutinin complex isolated from cultures ofC. botulinum. A controlled manufacturing process has been developed for the therapeutic toxin which is specially formulated to give a freeze-dried product having good stability.
Similar content being viewed by others
References
Arnon S (1981) Infant botulism, pathogenesis, clinical aspects and relation to crib death. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 331–345
Black JD, Dolly JO (1986) Interaction of125I-labelled botulinum neurotoxins with nerve terminals. J Cell Biol 103:521–534
Das Gupta BR, Sugiyama H (1972) A common subunit structure inClostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun 48:108–112
Dolly JO, Williams RS, Black JD, Tse CK, Hambleton P, Melling J (1982) Localisation of sites for 125-I labelled neurotoxin at the murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon 20:141–148
Dolly JO, Black JD, Williams RS, Melling J (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 307:457–460
Eisel J, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Hambermann E, Neimann H (1986) Tetanus toxin: primary structure expression inE. coli and homology with botulinum toxins. EMBO J 5:2495–2502
Fairweather NF, Lyness VA (1986) The complete neucleotide sequence of tetanus toxin. Nucleic Acids Res 14:7809–7812
Feldman RA, Morris JG, Pollard RA (1981) Epidemiological characteristics of botulism in the United States. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 271–284
Gonnering RS (1988) Negative antibody response to long-term treatments of facial spasm with botulinum toxin. Am J Ophthalmol 105:313–315
Hambleton P, Capel B, Bailey N, Heron N, Crooks A, Melling J (1981) Production, purification and toxoiding ofClostridium botulinum type A toxin. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 247–260
Hambleton P, Shone CC, Melling J (1987) Botulinum toxinstructure, action and clinical uses. In: Jenner P (ed) Neurotoxins and their parmacological implications. Raven Press, New York, pp 233–260
Kozaki S (1979) Interaction of type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn Schmiedeberg's Arch Pharmacol 308:67–70
Melling J, Allner K (1981) The containment of microorganisms. In: Norris JR, Richmond MH (eds) Essays in applied microbiology. Wiley, New York, pp 11/1–11/32
Melling J, Hambleton P, Shone CC (1988)Clostridium botulinum toxins: nature and preparation for clinical use. Eye 2:16–23
Molgo J, Thesleff S (1984) Studies on the mode of action of botulinum toxin type A at the frog neuromuscular junction. Brain Res 279:309–316
Murayama S, Syoto B, Oguma K, Iida H, Kubo S (1984) Comparison ofClostridium botulinum toxin types D and C1 in molecular property antigenicity and binding ability to rat brain synaptosomes. Eur J Biochem 142:487–492
Patrinely JR, Whiting AS, Anderson RL (1988) Local side effects of botulinum toxin infections. Adv Neurol 49:493–500
Poulain B, Wadsworth JDF, Maisey EA, Shone CC, Melling J, Tauc L, Dolly JO (1989) Inhibition of transmitter release by botulinum toxin A. Contribution of various fragments to the intoxication process. Eur J Biochem 185:197–203
Poulain B, Wadsworth JDF, Shone CC, Mochida S, Lande S, Melling J, Dolly JO, Taue L (1989) Multiple domains of botulinum neurotoxin contribute to its inhibiton of neurotransmitter release. J Biol Chem 264:21928–21933
Quinn N, Hallett M (1989) Dose standardisation of botulinum toxin. Lancet I:964
Report of Working Party on Leukaemia in Childhood (1986) Improvement for children with acute lymphoblastic leukaemia. Lancet I:408
Sakaguchi G, Kozaki S, Ohishi I (1984) Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JG, Jeljiaszewicz J (eds) Bacterial protein toxins. Academic Press, London, pp 433–443
Sanchez-Prieto J, Shira TS, Evans D, Ashton A, Dolly JO, Nicholls DG (1987) Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. Eur J Biochem 165:675–681
Scott AB (1989) Clostridial toxins as therapeutic agents. In: Simpson LL (ed) Botulinum neurotoxin and tetanus toxin. Academic Press, New York, pp 399–412
Scott AB, Rosenbaum AL, Collins CC (1973) Pharmacological weakening of extraocular muscles. Invest Ophthalmol 12:924–927
Shone CC (1987) Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson Ellis D (ed) Natural toxicants in foods. Horwood, Chichester, pp 11–57
Shone CC, Hambleton P (1989) Toxigenic clostridia. In: Minton NP, Clarke DJ (eds)Clostridia. Plenum Press, New York, pp 265–292
Shone CC, Hambleton P, Melling J (1985) Inactivation ofClostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Eur J Biochem 151:75–85
Shone CC, Hambleton P, Melling J (1987) A 50 kDa fragment from the NH2 terminus of the heavy subuinite ofClostridium botulinum type A neurotoxin forms channels in lipid vesides. Eur J Biochem 167:175–180
Simpson LL (1981) The origin, structural and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155–188
Thompson DE, Brehm JK, Oultram JD, Swinfield T-J, Shone CC, Atkinson T, Melling J, Minton NP (1990) The complete amino acid sequence of theClostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem 189:73–81
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hambleton, P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239, 16–20 (1992). https://doi.org/10.1007/BF00839205
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00839205